Amarin Reports First Quarter 2016 Financial Results and Provides Update on Operations Submitted by amarin on Fri, 12/08/2017 - 04:49 Home Read more about Amarin Reports First Quarter 2016 Financial Results and Provides Update on Operations
Amarin Announces Encore Presentation of Results of the Apolipoprotein C-III Post-Hoc Analysis From MARINE and ANCHOR Studies of Vascepa(R) at the European Society of Cardiology (ESC) 2015 Annual Congress Submitted by amarin on Fri, 12/08/2017 - 04:49 Home Read more about Amarin Announces Encore Presentation of Results of the Apolipoprotein C-III Post-Hoc Analysis From MARINE and ANCHOR Studies of Vascepa(R) at the European Society of Cardiology (ESC) 2015 Annual Congress
Amarin to Present at the Rodman & Renshaw 2015 Global Investment Conference Submitted by amarin on Fri, 12/08/2017 - 04:49 Home Read more about Amarin to Present at the Rodman & Renshaw 2015 Global Investment Conference
Amarin to Report Third Quarter 2015 Results and Host Conference Call on November 4, 2015 Submitted by amarin on Fri, 12/08/2017 - 04:49 Home Read more about Amarin to Report Third Quarter 2015 Results and Host Conference Call on November 4, 2015
Amarin Reports Third Quarter 2015 Financial Results and Provides Update on Operations Submitted by amarin on Fri, 12/08/2017 - 04:49 Home Read more about Amarin Reports Third Quarter 2015 Financial Results and Provides Update on Operations
EPA Therapy Added to Statin Therapy Showed Coronary Plaque Regression at Approximately Twice the Prevalence Compared to Statin Therapy Alone in Japanese Clinical Study Submitted by amarin on Fri, 12/08/2017 - 04:49 Home Read more about EPA Therapy Added to Statin Therapy Showed Coronary Plaque Regression at Approximately Twice the Prevalence Compared to Statin Therapy Alone in Japanese Clinical Study
Amarin Announces Agreement to Purchase $16.2 Million of Its Existing Exchangeable Notes and Pricing of $31.3 Million of New Exchangeable Notes Submitted by amarin on Fri, 12/08/2017 - 04:49 Home Read more about Amarin Announces Agreement to Purchase $16.2 Million of Its Existing Exchangeable Notes and Pricing of $31.3 Million of New Exchangeable Notes
Amarin to Present at the 27th Annual Piper Jaffray Healthcare Conference Submitted by amarin on Fri, 12/08/2017 - 04:49 Home Read more about Amarin to Present at the 27th Annual Piper Jaffray Healthcare Conference
Amarin to Present at the Oppenheimer & Co. Inc. 26th Annual Healthcare Conference Submitted by amarin on Fri, 12/08/2017 - 04:49 Home Read more about Amarin to Present at the Oppenheimer & Co. Inc. 26th Annual Healthcare Conference
Amarin Added to NASDAQ Biotechnology Index Submitted by amarin on Fri, 12/08/2017 - 04:49 Home Read more about Amarin Added to NASDAQ Biotechnology Index
